Trial Profile

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Xaluritamig (Primary) ; Xaluritamig (Primary) ; Abiraterone; Enzalutamide
Indications Prostate cancer
Focus Adverse reactions; First in man
Sponsors Amgen

Most Recent Events

06 Jun 2025 Planned End Date changed from 15 Aug 2028 to 17 Aug 2028.
30 Apr 2025 Results assessing association of baseline tumor and peripheral biomarker characteristics with efficacy in the first-in-human dose exploration trial, presented at the 116th Annual Meeting of the American Association for Cancer Research.
25 Mar 2025 Planned End Date changed from 17 Aug 2028 to 15 Aug 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com